AIM
AIM ImmunoTech Inc.
AIM ImmunoTech (AIM) Q2 2026 earnings
Published Aug 10, 2026
AI summary
- GAAP EPS −$0.43 missed the −$0.12 consensus by $0.31, up from −$3.68 a year ago.
- AIM ImmunoTech reported a net loss of $3.8 million for the second quarter of 2026.
- The company completed patient enrollment and dosing for its Phase 2 DURIPANC study in pancreatic cancer.
- Cash and cash equivalents increased to $9.9 million as of June 30, 2026, up from $3.0 million at year-end 2025.
- Research and development expenses decreased to $589,000, while general and administrative costs rose to $2.9 million.
Results vs analyst consensus
Revenue
Not reported in this release.
EPS · GAAP (street basis)
Reported · Diluted EPS (GAAP, street basis)
−$0.43
Consensus −$0.12
Missed by $0.31GAAP EPS: −$0.43
Consensus: Yahoo Finance · Q2 2026 · EPS estimate at release
Revenue display rounded; difference uses exact result.
Next quarter outlook
No guidance in this release.
What to watch
- The company reported a net loss of $3.8 million for the quarter compared to $2.8 million in the prior year period.
- General and administrative expenses increased significantly to $2.9 million from $1.5 million in the prior year.
Read original report
Source: AIM ImmunoTech Inc. press release · SEC Form 8-K exhibit 99.1